Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging

Completed

Conditions studied: Chronic Thromboembolic Pulmonary Hypertension

In brief

This study with evaluate blood flow in the lungs of patients prior to and after surgery for treatment.

Key facts

Study ID

NCT02114047

Run by

Massachusetts General Hospital

People needed

5

Starts

2014-02-01

Expected to finish

2017-01-01

Last updated by the study team

2017-03-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject is diagnosed with chronic thromboembolic pulmonary hypertension (WHO Group IV) and planning to undergo pulmonary thromboendarterectomy.
• Subject is male or female aged > or =18 years of age and < or = 70 years.
• Subject has undergone RHC within six months of entering the study.
• The subject is capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
• A signed and dated written informed consent is obtained from the subject.
• Available to complete the study.
• Able to lie flat and able to perform a 30 second breath hold.

You may not qualify if…

• FEV1 and/or TLC < 70% predicted.
• Inability to perform the study (by primary MD or investigator assessment).
• Inability to perform the respiratory maneuvers necessary for the exam.
• Subjects who have a past or present disease, which as judged by the Investigators may affect the outcome of this study.
• The subject has suspected history of drugs or alcohol abuse within the six months prior to the screening visit.
• The subject is a woman of childbearing potential who is pregnant, seeking to become pregnant, or has a positive pregnancy test.
• Subject with clinical instability in the judgment of the investigator, with a heart rate > 120 bpm, respiratory rate > 24, SpO2 < 88%, blood pressure < 90/60 or > 140/90 or fever > 101, or subjects with hospitalization for progression of pulmonary hypertension or right heart failure in the three months prior to the study.
• Subject with diagnosis of active tuberculosis, lung cancer, clinically overt bronchiectasis, allergic rhinitis, asthma, heart failure, ischemic heart disease, or COPD.
• Subject that had a respiratory tract infection in the 4 weeks prior to the screening visit and throughout the duration of the study.
• The subject has been exposed to a radiation dose over the past year that, when added to the radiation dose expected in this study, would exceed permissible yearly exposure as determined by the MGH radiation safety committee.

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.